Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Price Drop

<< Previous

Bullboard Posts

Next >>

Post by nodaytraderon May 02, 2022 12:51pm

150 Views

Post# 34647986

Price Drop

On Friday, AGN announced promising results from a study on treatment of Chronic Kidney Didease.
On the very next trading day, we have a slew of mini trades that knock millions off the company's capital value.

what is going on? Are any of the regulators, who are supposed to guard investor interests, liking into this? Have they even noticed?

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for Sept. 19, 2024